Plus Therapeutics Inc - ESG Rating & Company Profile powered by AI
Alternative companies in the rating industry group for Plus Therapeutics Inc are displayed. The analysis of Plus Therapeutics Inc is prepared by All Street Sevva using advanced NLP. The webpage is a free E,S&G report covering Plus Therapeutics Inc.
Plus Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.1; made up of an environmental score of 4.0, social score of 0.0 and governance score of 5.3.
3.1
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1299 | Active Fine Chemicals Ltd | 3.2 | Medium |
1299 | Yuhan Corp | 3.2 | Medium |
1309 | Plus Therapeutics Inc | 3.1 | Medium |
1309 | Champions Oncology Inc | 3.1 | Medium |
1309 | IBEX Technologies Inc | 3.1 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Plus Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Does Plus Therapeutics Inc disclose current and historical energy intensity?
Does Plus Therapeutics Inc report the average age of the workforce?
Does Plus Therapeutics Inc reference operational or capital allocation in relation to climate change?
Does Plus Therapeutics Inc disclose its ethnicity pay gap?
Does Plus Therapeutics Inc disclose cybersecurity risks?
Does Plus Therapeutics Inc offer flexible work?
Does Plus Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Plus Therapeutics Inc disclose the number of employees in R&D functions?
Does Plus Therapeutics Inc conduct supply chain audits?
Does Plus Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Plus Therapeutics Inc conduct 360 degree staff reviews?
Does Plus Therapeutics Inc disclose the individual responsible for D&I?
Does Plus Therapeutics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Plus Therapeutics Inc disclose current and / or historical scope 2 emissions?
Does Plus Therapeutics Inc disclose water use targets?
Does Plus Therapeutics Inc have careers partnerships with academic institutions?
Did Plus Therapeutics Inc have a product recall in the last two years?
Does Plus Therapeutics Inc disclose incidents of discrimination?
Does Plus Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Has Plus Therapeutics Inc issued a profit warning in the past 24 months?
Does Plus Therapeutics Inc disclose parental leave metrics?
Does Plus Therapeutics Inc disclose climate scenario or pathway analysis?
Does Plus Therapeutics Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Plus Therapeutics Inc disclose the pay ratio of women to men?
Does Plus Therapeutics Inc support suppliers with sustainability related research and development?
Does Plus Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Plus Therapeutics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Plus Therapeutics Inc involved in embryonic stem cell research?
Does Plus Therapeutics Inc disclose GHG and Air Emissions intensity?
Does Plus Therapeutics Inc disclose its waste policy?
Does Plus Therapeutics Inc report according to TCFD requirements?
Does Plus Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Plus Therapeutics Inc disclose energy use targets?
Does Plus Therapeutics Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Plus Therapeutics Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Plus Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.